Australia markets closed

Amoy Diagnostics Co., Ltd. (300685.SZ)

Shenzhen - Shenzhen Delayed price. Currency in CNY
Add to watchlist
23.07-0.13 (-0.56%)
At close: 03:04PM CST
Full screen
Previous close23.20
Bid23.07 x 0
Ask23.08 x 0
Day's range22.96 - 23.60
52-week range22.03 - 48.88
Avg. volume2,917,058
Market cap9.185B
Beta (5Y monthly)0.67
PE ratio (TTM)42.72
EPS (TTM)0.54
Earnings date22 Apr 2022 - 25 Apr 2022
Forward dividend & yield0.23 (0.99%)
Ex-dividend date31 May 2022
1y target est45.36
  • PR Newswire

    Qiming's Portfolio Company InventisBio Lists on STAR Market

    Qiming Venture Partners' portfolio company InventisBio (SHSE: 688382), a leading company in innovative drug development, today listed on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange. The issue price is CNY 18.12 per share, representing a market cap of CNY 10.419 billion.

  • PR Newswire

    Qiming Venture Partners Announces Closing of Funds Totaling US$3.2 Billion

    Qiming Venture Partners announced today the closing of its latest funds totaling US$3.2 billion, including USD Fund VIII at US$2.5 billion and the first closing of RMB Fund VII at RMB 4.7 billion (or US$ 700 million).

  • GlobeNewswire

    AmoyDx Enters into Master Collaboration Agreement with AstraZeneca for Multiple Companion Diagnostics Programs in China, EU and Japan

    SHANGHAI, China, April 18, 2022 (GLOBE NEWSWIRE) -- Amoy Diagnostics Co., Ltd (AmoyDx), a China based innovative molecular diagnostics company (SZSE: 300685), today announces that it has entered into a Master Collaboration Agreement (Agreement) with AstraZeneca (LSE/STO/Nasdaq: AZN), a global, science-led biopharmaceutical company. The master collaboration agreement enables the Parties to collaborate in the development and commercialization of AmoyDx assays that may cover any type of indication